{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:57:15Z","timestamp":1781125035303,"version":"3.54.1"},"reference-count":79,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Breast cancer survivors (BCS) face a significantly higher risk of treatment-induced bone loss compared with the general population. Despite clinical guidelines, baseline bone mineral density (BMD) screening and indicated pharmacologic interventions remain consistently underutilized in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN<\/jats:title>\n                    <jats:p>This review synthesizes current evidence regarding the pathophysiology and incidence of bone loss in BCS. We evaluate the impact of cytotoxic and endocrine therapies on skeletal health and summarize contemporary guidelines for the screening, prevention, and management of cancer treatment-induced bone loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Up to 80% of patients with breast cancer experience bone loss during treatment, primarily driven by iatrogenic estrogen depletion. Fewer than half of patients starting endocrine therapy with aromatase inhibitors receive a baseline dual-energy x-ray absorptiometry scan as recommended by ASCO guidelines, and nearly 50% of treatment-eligible patients remain untreated. Proactive mitigation is essential and must include baseline BMD screening and fracture risk assessment (FRAX) at the initiation of endocrine therapy, with interval monitoring frequency that is tailored by baseline risk. In patients with osteoporosis or high-risk osteopenia, antiresorptive agents effectively improve BMD and reduce fracture-associated morbidity and mortality. A multipronged approach incorporating lifestyle factors such as calcium\/vitamin D supplementation, smoking cessation, and weight-bearing exercise is critical for optimizing long-term skeletal health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Bone loss is a nearly universal consequence of breast cancer therapy. Integrating proactive BMD monitoring, standardized FRAX, and timely initiation of antiresorptive therapy into survivorship care is vital to improve long-term outcomes and functional independence in BCS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-26-00169","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:59:12Z","timestamp":1781121552000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Management of Bone Health in Breast Cancer Survivors"],"prefix":"10.1200","author":[{"given":"Kumar","family":"Shivam","sequence":"first","affiliation":[{"name":"Department of Cardiothoracic Surgery, Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8877-4358","authenticated-orcid":true,"given":"Jessica","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah, Salt Lake City, UT"},{"name":"Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6915-1820","authenticated-orcid":true,"given":"Faisal","family":"Aljabrain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karma-Jaya P.","family":"Elliott","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-4184","authenticated-orcid":true,"given":"Jairam","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT"},{"name":"Division of Oncology, Department of Internal Medicine, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-510X","authenticated-orcid":true,"given":"Kristen C.","family":"Kelley","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT"},{"name":"Division of Oncology, Department of Internal Medicine, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra053077"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2010.02.014"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2530-3"},{"key":"e_1_3_4_5_2","first-page":"Cd013538","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui KT","year":"2020","unstructured":"Bui KT, Willson ML, Goel S, et al: Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev 3:Cd013538, 2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.751"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980200001"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060508"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70003-7"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4882"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.3515"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261302"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.148"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.78"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000692"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13866"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1408-1"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3306"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2307353"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21335"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3809"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.5.552"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","unstructured":"Geoffrey Bostany YC Liton F Sparks J et al: New-onset osteopenia\/osteoporosis among long-term survivors of breast cancer: Role of hormone therapies and metabolic risk factors. Presented at: 2025 ASCO Annual Meeting; 2025; Chicago IL. Session Symptom Science and Palliative Care","DOI":"10.1200\/JCO.2025.43.16_suppl.12046"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1780-5"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-813073-5.00056-3"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89059-0"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27154"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84698-1"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1419-7"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12586"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.314"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1622-5"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.43156"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01160"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032312"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604700"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30621-1"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104162"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad078"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01013-X"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01696"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.018341"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06458-z"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.07.013"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2017.03.001"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01622200"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0543-5"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2794-2"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu008"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0385"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02647"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806285"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0261"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60995-3"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30862-3"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200162"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30687-4"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0852-3"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.04.022"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.11.020"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.16.S3.1"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3705"},{"key":"e_1_3_4_65_2","unstructured":"FDA. Prolia (Denosumab): Drug Safety Communication\u2014FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease. US Food & Drug Administration. 2024"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2022.02.008"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2927"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1998"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3170"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1075-9"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834015598536"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000002116"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810118"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2014.07.005"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1734-y"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1768"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2708"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.09.005"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05570-0"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:59:14Z","timestamp":1781121554000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":79,"alternative-id":["10.1200\/OP-26-00169"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00169","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"2026-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00169"}}